Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
|
|
- Gordon Snow
- 5 years ago
- Views:
Transcription
1 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen
2 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
3 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
4 Adjunctive Antithrombotic Therapy - Goals - Prevention of Restenosis Thus far futile (except abciximab for diabetics in EPISTENT) Prevention of Subacute Stent Thrombosis Aspirin & thienopyridine (ISAR, STARS, FANTASTIC, MATTIS) Prevention of Acute Thrombosis and Infarction Aspirin (Barnathan, Circulation 1987; Schwartz, N Engl J Med 1988) Anti-GP IIb/IIIa Pretreatment with thienopyridine Anticoagulants
5 Adjunctive Antithrombotic Therapy for Prevention of Acute Thrombosis and Peri-Interventional Infarction Anti-GP IIb/IIIa Pretreatment with thienopyridine Anticoagulants
6 Efficacy of GP IIb/IIIa Blockade for PCI PCI Studies Abciximab EPIC (bolus arm) EPILOG EPISTENT (stent arms) Eptifibatide IMPACT-II ESPRIT Tirofiban RESTORE PCI Subgroups Eptifibatide PURSUIT (death&mi) Tirofiban PRISM-PLUS Comparison Abciximab vs. Tirofiban TARGET Odds Ratio for 30-Day Death, MI & Urg. TVR
7 Rate of Death & MI [%] Rate of Death & MI [%] Efficacy of GP IIb/IIIa Blockade Depending on Risk Positive Troponin T Negative Troponin T 30 P=0.001 P= n.s. n.s Day 30 Day Day 30 Day 180 Hamm et al., N Engl J Med 1999 Placebo Abciximab
8 Adjunctive Antithrombotic Therapy for Prevention of Acute Thrombosis and Peri-Interventional Infarction Anti-GP IIb/IIIa Pretreatment with thienopyridine Anticoagulants
9 Clopidogrel Pretreatment and Early Risk of PCI 30-Day Death, MI & Urg. TVR (%) 10 8 PCI-CURE CREDO P=0.05 No Pretreatment Pretreatment P= mg + 75 mg for 300 mg median of 10 days < 6 h 6-24 h
10 Rapid Effect with High Loading Dose of Clopidogrel Platelet aggregation (%) Platelet aggregation (%) 300 mg P<0.01 n.s. n.s. 600 mg n=10 n=10 n=10 n=10 n=514 n=204 2 h 48 h h > 6 h Müller et. al., Heart 2001 Hochholzer et. al., Circulation in press
11 Pretreatment with Thienopyridine and Early Risk of PCI PCI-CURE, n = 2658 CREDO (full effect), n = 473 EPISTENT, n = 809 ESPRIT*, n = 1024 Pooled, n = 4964 Relative 30-Day Risk of Death, MI, Urg. TVR *1-year Death&MI Mehta SR, Lancet 2001; Steinhubl SR, Circulation 2001 & JAMA 2002; Tcheng JE, pers. comm.
12 Bleeding Risk of CABG After Clopidogrel Early Major/Life Threatening Bleeding (%) 10 P= P= Placebo Clopidogrel Fox KA et al., Circulation < 4 Days > 4 Days After Discontinuation of Study Drug
13 Risk/Benefit Ratio of Clopidogrel in CURE CV Death, MI, Stroke & Life Threatening Bleeding (%) 15 P< Events Prevented/Incurred per Life Threatening 5 Bleeding Placebo Clopidogrel Fox KA et al., Circulation CV Death, Infarction, Stroke
14 Clopidogrel Pretreatment Plus GP IIb/IIIa Blockade? 30-Day Death, MI & Urg. TVR (%) 15 P=0.17 P= P= No Pretreatment Pretreatment 0 Abciximab Tirofiban Eptifibatide TARGET Chan AW et al., J Am Coll Cardiol 2003; Tcheng JE, pers. comm. ESPRIT* *1-year Death&MI
15 Efficacy of Thienopyridines with GP IIb/IIIa Blockade Ticlopidin EPISTENT (Abciximab), n=794 Clopidogrel ESPRIT* (Eptifibatid), n=1040 Pooled, n=7,021 TARGET (Abciximab), n=2411 TARGET (Tirofiban), n=2398 CREDO (Mixed), n=378 Steinhubl SR, Circulation 2001 & JAMA 2002; Chan AW et al., J Am Coll Cardiol 2003; Tcheng JE, pers. comm. Relative 30-Day Risk of Death, MI & Urg. TVR *1-year Death&MI
16 Are GP IIb/IIIa antagonists needed, if the patient is on clopidogrel? ISAR-REACT
17 Major Selection Criteria Included Elective percutaneous coronary intervention Pretreatment with 600 mg clopidogrel at least 2 hours before PCI Not Included ST-segment displacement Troponin-T level > 0.03 ng/ml, recent (<14 days) MI Insulin-dependent diabetes mellitus Kastrati A et al., N Engl J Med 2004
18 ISAR-REACT: Efficacy and Safety Analysis 30-Day Rate (%) 6 P=0.91 P= P= 0.37 P=0.007 Placebo Abciximab Death & MI Urgent TVR Major bleed 0.9 Transfusion Kastrati A et al., N Engl J Med 2004
19 ISAR-REACT: Outcome in Higher Risk Subgroups Diabetes (non-insulin dep.) Yes No Angina class III/IV or Prior myocardial infarction Yes No PCI in complex lesions Yes No Relative Risk Kastrati et al., N Engl J Med Abciximab better Placebo better
20 ISAR-REACT: 1-Year Outcome Event-free survival, % 100 P= Death: 2.1% vs 2.4%, P=0.66 MI: 4.2% vs 4.3%, P= Abciximab Placebo 0 Schömig A et al., Eur Heart J, in press Months after randomisation
21 Adjunctive Antithrombotic Therapy for Prevention of Acute Thrombosis and Peri-Interventional Infarction Anti-GP IIb/IIIa Pretreatment with thienopyridine Anticoagulants
22 Anticoagulants: Alternatives to Heparin Enoxaparin 30-Day Rate (%) 15 P=0.27 P= Bivalirudin In-Hospital Rate (%) 15 P=0.42 P< Heparin Enoxaparin Bivalirudin 5 0 Death & MI Major bleed Death, MI & emerg. CABG Major bleed SYNERGY-PCI, TCT 2004; Bittl et al., N Engl J Med 1995
23 Can bivalurudin replace GP IIb/IIIa blockade? REPLACE-2
24 Major Selection Criteria Included Urgent or elective percutaneous coronary intervention Not Included Acute myocardial infarction Lincoff et al., JAMA 2003
25 REPLACE-2: Primary Endpoint Heparin + Anti GP IIb/III Bivalirudin + bail-out 7.2% P= P=0.26 P=0.43 P=0.44 P< Composite Death 6.2 MI Urgent TVR Major bleeding Lincoff et al., JAMA 2003
26 Outcome in Various Subgroups Diabetes Yes No ACS present Yes No Thienopyridine pretreatment Yes No Relative Risk of Death, MI, Urgent TVR Abciximab Eptifibatide Lincoff et al., JAMA Bivalirudin better Anti GPIIb/IIIa better
27 REPLACE-2: Long-Term Outcome 6-month rates MI: 7.4% vs 8.2%, P=0.24 TVR: 11.4% vs 12.1%, P=0.66 Lincoff et al., JAMA 2004
28 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
29 Abciximab and Stent in Diabetics 6-month rate of death, MI and TVR (%) 30 P=0.005 P= Abciximab Placebo Diabetes No Diabetes Marso et al., Circulation 1999
30 Marso et al., Circulation 1999 Abciximab and Stent in Diabetics
31 Marso et al., Circulation 1999 Abciximab and Stent in Diabetics
32 Marso et al., Circulation 1999 Abciximab and Stent in Diabetics
33 Improved Survival After PCI with Abciximab Cumulative incidence of death (%) P = Diabetics, placebo Non-diabetics, placebo Diabetics, abciximab Non-diabetics, abciximab Bhatt DL et al., J Am Coll Cardiol 2000
34 ISAR-SWEET: Abciximab After Clopidogrel Loading in Diabetics? Mehilli J et al., Circulation 2004
35 ISAR-SWEET: Abciximab After Clopidogrel Loading in Diabetics? 6-month rate of death, MI and TVR (%) 50 P=0.01 P= Abciximab Placebo 10 0 Mehilli J et al., Circulation 2004 Restenosis 6 months TLR 12 months
36 REPLACE-2: Outcome in Diabetics 30-days Diabetes No Diabetes 1-year Diabetes No Diabetes Relative Risk of Death, MI, Urgent TVR Bivalirudin better Anti GPIIb/IIIa better Lincoff et al., JAMA 2003 & 2004
37 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
38 Preinterventional Rate of Death and Infarction 6% 4% 2% N=12,296 P= % 2.9% Control Pooled GP IIb/IIIa-Antagonist 0% 0h 24h 48h 72h Boersma et al., Circulation 1999
39 Does Antithrombotic Pretreatment Reduce the Risk of Subsequent PCI?
40 Intracoronary Thrombi in Unstable Angina Zhao et al., Circulation 1999
41 Lower Thrombus Load After GP IIb/IIIa Inhibition Lesions with Moderate/Large Thrombus (%) 30 P= % 17.1% 0 Zhao et al., Circulation 1999 Heparin alone Tirofiban + Heparin
42 Cooling-off before PTCA and Risk of Death and Infarction day 2-3 days 4-7 days 8-30 days Simoons Eur Heart J 2000 Peri- & Postinterventional
43 Randomization Cooling-off: Antithrombotic pretreatment for 72 to 120 hours Early intervention: Antithrombotic pretreatment for less than 6 hours Neumann et al., JAMA 2003
44 Antithrombotic Regimen Aspirin: Pretreatment: (Duration as randomized) initial iv-bolus of 500 mg, 100 mg bid. Clopidogrel: 600 mg loading dose 75 mg bid Tirofiban: Heparin: 10 µg/kg Bolus, 0,10 µg/kg/min 60 U/kg bolus infusion (PTT 60-85s) Peri/Postinterventional: 2 x 100 mg 75 mg bid for 3 d, 1 x 75 mg 0,15 µg/kg/min für 24h 60 U/kg bolus Neumann et al., JAMA 2003
45 Study Population Early Intervention n=203 Cooling-Off n=207 Troponin T 34% 34% 35% 32% ST-segment Both 32% 32% Neumann et al., JAMA 2003
46 ISAR-COOL: Primary Endpoint After Catheterization Combined incidence of death and MI (%) Early intervention P=0.96 Cooling-off 0 Neumann et al., JAMA Days after randomization
47 Risk of Pretreatment Death and MI 5% 4% 3% TACTICS: CONSERVATIVE CAPTURE PRISM-PLUS PURSUIT 4,4% 2% 1% 0% 1,7% TACTICS: INVASIVE Boersma et al., Circulation 1999; Cannon et al., ESC 2001
48 Cooling-off before PTCA and Risk of Death and Infarction day 2-3 days 4-7 days 8-30 days Simoons Eur Heart J 2000 Preinterventional Peri- & Postinterventional
49 Cooling-off before PTCA and Risk of Death and Infarction day 2-3 days 4-7 days 8-30 days Simoons Eur Heart J 2000 Total Preinterventional Peri- & Postinterventional
50 Clinical Outcome and Duration of Pretreatment - TACTICS - Patients with primary endpoint within 6 months [%] >48 Duration of pretreatment [h] Cannon et al., ESC 2001
51 ISAR-COOL: Primary Endpoint Before and After Catheterization Number of events (death & MI) 15 P=0.002 P= Cooling-off Early intervention 5 0 Before Neumann et al., JAMA Catheterization After
52 ISAR-COOL: Incidence of Primary Endpoint Combined incidence of death and MI (%) 15 Cooling-off 10 P= Early intervention 0 Neumann et al., JAMA Days after randomization
53 Cumulative Incidence of Primary Endpoint Combined incidence of death and MI (%) % Cooling-off 5.6% Early intervention 0 Kastrati et al., TCT Months after randomization
54 Left Ventricular Function %LV % P=0.13 Perfusion Defect Size at 30-Day SPECT 0 P=0.005 LV Ejection Fraction at 6-Month Angiography Cooling-off Early intervention Kastrati et al., TCT 2004
55 Benefit of GP IIb/IIIa Blockade in ACS Meta-Analysis of Six Major Trials (31,402 Patients) All patients with ACS Patients with ACS, undergoing PCI within 5 days Relative 30-Day Risk of Death and MI Anti GPIIb/IIIa better Boersma E et al. Lancet 2002
56 Clopidogrel and/or anti-gp IIb/IIIa: Differential Efficacy Depending on Risk Profil Event rate [%] 15 P< P<0.05 Event rate [%] 15 n.s. 10 P<0.05 Control Tirofiban Heeschen et al., Lancet 1999 Clopidogrel 5 5 CURE, ACC PRISM CURE Marker positive 0 PRISM CURE Marker negative
57 GP IIb/IIIa Blockade While on Thienopyridines Relative 30-Day Risk of Death, Infarction, Urgent Reintervention TARGET: Pretreatment with Clopidogrel Abciximab vs. Tirofiban Topol et al., N Engl J Med 2000
58 Are GP IIb/IIIa antagonists needed in high-risk ACS, if the patient is on clopidogrel? ISAR-REACT-2
59 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
60 ADMIRAL - Angiographic Patency TIMI 3 Flow (% of Patients) 100 p = p = p = Placebo Abciximab p = Prior To PCI Immediately Post-PCI 24 hour Post-PCI 6 month Post-PCI Montalescot et al., N Engl J Med 2001
61 Abciximab for PCI in AMI: Microvascular Reperfusion and Recovery of Contraction D 30 Peak flow velocity (cm/s) p=0.024 D 0.8 Wall motion index (SD/chord) p= Neumann et al., Circulation 1998 Abciximab Heparin 95%-confidence interval
62 Abciximab and ST-Resolution After Stenting: Results from ACE Antoniucci et al., J Am Coll Cardiol 2003
63 Infarct Size in ACE Infarct Size (% of LV) 30 p= Antoniucci et al., J Am Coll Cardiol Stent Stent + Abciximab
64 RAPPORT, Brener et al. (PTCA) Circulation 1999 ISAR-2 Neumann et al. (Stent) J Am Coll Cardiol 2000 ADMIRAL Montalescot et al (Stent) N Engl J Med, 2001 CADILLAC Abciximab for PCI in AMI: Clinical Outcome Stone et al. (Stent/PTCA) N Engl J Med, Days 6 Months ACE Antoniucci et al. (Stent) J Am Coll Cardiol 2003 Pooled Relative Risk of Death+MI+TVR Abciximab vs Control
65 Abciximab for PCI in AMI: 6 to 12-Month Mortality ADMIRAL 300 CADILLAC 2082 RAPPORT 483 ISAR ACE 394 Petronio et al. 89 Pooled Abciximab better Placebo better De Luca G et al., submitted
66 Are GP IIb/IIIa antagonists needed in acute myocardial infarction, if the patient is on clopidogrel or receives bivalirudin? BRAVE-3 HORIZONS
67 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
68 Duration of Clopidogrel Administration in Various Studies Ravel: Sirius: E-Sirius: C-Sirius Taxus I: Taxus II: Taxus IV: 8 weeks 3 months 2 months 2 months 6 months 6 months 6 months
69 Mortality Within 6-12 Months after DES Babapulle MN et al., Lancet 2004
70 Incidence of Myocardial Infarction within 6-12 Months after DES Babapulle MN et al., Lancet 2004
71 Incidence of Stent Thrombosis within 6-12 Months after DES Ravel Sirius C-Sirius E-Sirius pooled Taxus-I Taxus-II Taxus-IV pooled Babapulle MN et al., Lancet Rate of Stent Thrombosis (%) DES BMS
72 Rate of Stent Thrombosis [%] Rate of Stent Thrombosis within 6-12 Months after DES x SIRIUS (n=1510) TAXUS IV (n=1314) TAXUS VI (n=219) ARTS II (n=606) Cypher- Bifurcation (n=86)
73 Stent Thrombosis TAXUS IV (n=625) % (n=7) p 0.77 Control (n=613) % (n=5) 0 0,5 1 1,5 30 days 30 days to 1 year 1 year to 2 years
74 Reports on Late Stent Thrombosis after DES Mc Fadden EP et al., Lancet 2004 Paclitaxel-eluting stent: Day 343 Paclitaxel-eluting stent: Day 442 Sirolimus-eluting stent: Day 335 Sirolimus-eluting stent: Day 375 After discontinuation of aspirin and clopidogrel Virmani R et al., Circulation 2004 Sirolimus-eluting stent: Day 550 Hypersensitivity reaction with occlusive thrombus
75 Hypersensitivity Reaction after Sirolimus-Eluting Stent Late Occlusive Thrombus Inflammation within media Giant cells around polymer remnant Virmani R et al., Circulation 2004
76 Open Thienopyridine Benefit of Long-Term Therapy with Clopidogrel - PCI-CURE - Vasc. Death or Myocardial Infarction [%] Placebo Clopidogrel Days Mehta SR et al., Lancet 2001
77 Risk Reduction by Clopidgrel: Day 30 to End of Study - PCI-CURE - Relative Risk Vasc. Death and Infarction Vasc. Death, Infarction, Rehospitalisation Mehta SR et al., Lancet 2001
78 Benefit of Long-Term Therapy with Clopidogrel in CREDO Cumulative Incidence of Death, Infarction and Stroke [%] 6 Placebo Clopidogrel 2 1 Relative Risk: 0.63 ( ); P = Days Steinhubl et al., JAMA 2002
79 CHARISMA: Clopidogrel for Secondary Prevention Patients 45 years R with high risk of athero-thrombotic complications Randomisation: n = 15,200 (event driven) Clopidogrel 75 mg daily (n = 7,600) Placebo (n = 7,600) All Patients receive additional aspirin ( mg daily).
80 Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Overview of Agents and Strategies Special Subsets - Diabetics - ACS without ST-elevation - Myocardial infarction with ST-elevation - Drug-eluting stents - Indication for oral anticoagulation
81 Efficacy of Dual Antiplatelet Therapy Anticoagulation plus Aspirin ISAR STARS MATTIS FANTASTIC pooled Odds Ratio for death, myocardial infarction and target vessel revascularization Ticlopidine plus Aspirin better Control therapy better
82 Fibrinogen Receptor Activation After Stenting percentage of LIBS1-positive platelets 40 aspirin group ticlopidine group P= days after stent implantation Neumann et al., J Am Coll Cardiol 1997
83 Inadequate Platelet Inhibition by Ticlopidine Alone Platelet aggregation (%) Ticlopidine + aspirin Ticlopidine alone 50 0 Collagen-induced ADP-induced Rupprecht HJ et al., Circulation 1998
84 Clopidogrel versus Aspirin in CAPRIE Caprie Investigators, Lancet 1996
85 Clopidogrel versus Aspirin in CAPRIE: No Benefit in Cardiac Patients Caprie Investigators, Lancet 1996
86 Anticoagulation and Dual Antiplatelet Therapy Mayo-Clinic Experience 66 Patients No MACE 6 Patients with Readmission for Bleeding: Bleeding from colon polyps, transfusion Day 14 Hematuria secondary to urolithiasis Day 15 Peptic ulcer Day 9 Groin haematoma Day 2 (INR 1.0) Nose bleeding Minor ear bleeding Orford JL et al., Am Heart J 2004
87 Anticoagulation and Dual Antiplatelet Therapy Herz-Zentrum Bad Krozingen 161 Patients from Oct until Oct (2.0 % of all PCI) 30-day MACE: n = 7 (4.3 % [95%-CI: 1.2 % %]) Death: n=4 (2.5 %) unknown ischemic stroke intracerebral bleeding after fall stent thrombosis No lethal infarction: n = 0 Reintervention: n = 3 (1.9%) Bleeding complications: n=4 (2.5 % [95%-CI: 0.1%-4.9%]) Intracerebral bleeding after fall n = 1 Surgical revision for groin bleeding n = 2 Gastro-intestinal bleeding n = 1
88 ACTIVE Study Design Atrial Fibrillation Increased Risk of vascular events Contraindication to oral anticoagulation Clopidrogrel + Aspirin vs oral anticoagulation (INR 2-3) Clopidrogrel + Aspirin vs Placebo + Aspirin n = 6,000 completed Irbesartan vs Placebo Follow-up after 3 years about 4,000 still running
89 Adjunctive Antithrombotic Therapy Low-to-intermediate risk patients Effective clopidogrel pretreatment (ISAR-REACT-regimen) or bivalirudin (REPLACE-2 regimen) can replace GP IIb/IIIa blockade Insulin-Treated Diabetics Effective clopidogrel pretreatment or bivalirudin are potential alternatives to GP IIb/IIIa blockade High Risk Acute Coronary Syndromes (incl. STEMI) Based on currently available evidence: Triple antiplatelet therapy plus heparin
90 Continuation of Antithrombotic Treatment Duration of Dual Antiplatelet Therapy Optimal: 1 year Minimal: Bare stents 4 weeks Sirolimus-eluting stents 2 months Paclitaxel-eluting stents 6 months Atrial fibrillation with low intermediate risk Withholding of oral anticoagulation for the duration of dual antiplatelet therapy Patients with strict indication for oral anticoagulation Combination with dual antiplatelet therapy
P2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAntiplatelet Therapy After PCI: How Much and How Long?
Antiplatelet Therapy After PCI: How Much and How Long? Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Antiplatelet Therapy after PCI: How much and how long? The simplest and extreme response: Give
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationDauer der doppelten Plättchenhemmung nach AMI / Stent
Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch DAPT after Stenting 257 patients with PCI & stent: ASS &
More informationStent Thrombosis Importance of Pharmacotherapy
Stent Thrombosis Importance of Pharmacotherapy George D. Dangas, MD, FSCAI Columbia University Medical Center Cardiovascular Research Foundation New York City SCAI-2007 Orlando, FL Presenter Disclosure
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationAntiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003
Antiplatelet therapy and Coronary Interventions Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003 Objectives Pharmacology of GP IIb/IIIa inhibitors and Monitoring of Platelet Inhibition
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationOptimal antithrombotic therapy:
Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationBivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany
Bivalirudin should be indicated for all patients with STEMI Adnan Kastrati Deutsches Herzzentrum, Munich, Germany 1 Heparin+IIb/IIIa, heparin alone or bivalirudin in STEMI: Do we have the answer? 2 Heparin+IIb/IIIa,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationPathophysiology of ACS
Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationUpdate on the management of STEMI. Elliot Rapaport, M.D. San Francisco, CA December 14, 2007
Update on the management of STEMI Elliot Rapaport, M.D. San Francisco, CA December 14, 2007 Universal MI Definition Committee 2007 Recommendations Type 1 Spontaneous MI associated with ischemia and due
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationTHE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH?
THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH? Paul I. Oh, 1 Eric A. Cohen, 2 Nicole Mittmann, 3, 4 Soo Jin Seung 4 1 Division of Clinical Pharmacology, Sunnybrook
More informationThe Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 12, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.09.015 STATE-OF-THE-ART
More informationPatient characteristics Intervention Comparison Length of follow-up
ANTIPLATELET CHAPTER Aspirin compared with placebo Ref ID: 4158 Reference Antithrombotic TC. Collaborative meta-analysis randomised trials antiplatelet therapy for prevention death, myocardial infarction,
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationManual of Interventional Cardiology
782 PLATELET GLYCOPROTEIN IIb/IIIa RECEPTOR ANTAGONISTS (Tables 34.15, 34.16) Activation of the platelet glycoprotein (GP) IIb/IIIa receptor complex constitutes the final common pathway for platelet aggregation,
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More informationAntiplatelet Therapy. Briain Mac Neill
Antiplatelet Therapy Briain Mac Neill Galway University Hospital & National University of Ireland Galway Milestones in ACS Management Anti-Thrombin Rx Heparin LMWH Bivalirudin Anti-Platelet Rx Aspirin
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationAngioplastica coronarica nel paziente anziano ad alto rischio emorragico
Attualità in Cardiologia Aprilia, Enea Hotel 22 ottobre 2011 Angioplastica coronarica nel paziente anziano ad alto rischio emorragico Fabrizio Tomai, MD, FACC, FESC Dept. of Cardiovascular Sciences - Interventional
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationIssues in the Management of Diabetic Patients with Cardiovascular Disease
Issues in the Management of Diabetic Patients with Cardiovascular Disease Elliot Rapaport, MD December 13, 2008 1 Hyperglycemia and Acute Coronary Syndromes 2 Effect of Hyperglycemia in STEMI Impairs microvascular
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More information